Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lanadelumab - Takeda

Drug Profile

Lanadelumab - Takeda

Alternative Names: Anti-plasma kallikrein mAb; Anti-plasma kallikrein monoclonal antibody; DX-2930; Lanadelumab-flyo; SHP 643; TAK-743; TAKHZYRO

Latest Information Update: 26 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dyax
  • Developer Dyax; Shire; Takeda
  • Class Antivirals; Eye disorder therapies; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Plasma kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Phase I/II COVID 2019 infections
  • Phase I COVID-19 pneumonia
  • Discontinued Diabetic macular oedema

Most Recent Events

  • 16 Mar 2021 9318144: DT, KDM, Intro update
  • 12 Mar 2021 Preregistration for Hereditary angioedema (In adolescents, In children, In the elderly, In adults, Prevention) in Japan (SC)
  • 10 Feb 2021 Takeda initiates a phase III Expanded Access Programme for Hereditary angioedema (In adolescents, In adults, In children, In the elderly) in Japan (SC, Injection) in February 2021 (NCT04687137)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top